Increased aggregation and secretion responses of human platelets when loaded with the calcium fluorescent probes quin2 and fura-2.
Incorporation into human platelets of the calcium fluorescent indicators quin2 or fura-2 at low concentrations used to measure intracellular free calcium leads to the potentiation of the effects of agonists on platelets. This was shown by increased aggregatory and secretory responses of quin2 or fura-2 loaded platelets after stimulation with ADP, PAF and with low concentrations of thrombin, collagen, the endoperoxide analog U-46619 and the calcium ionophore A 23187. Quin2 and fura-2 mediated platelet sensitisation could be due to altered arachidonic acid metabolism since it was inhibited by prior treatment with the cyclooxygenase inhibitor acetylsalicylate. In contrast, platelets loaded with higher concentrations of calcium chelators exhibited diminished aggregation responses to all aggregating agents. This latter effect was accompanied by increased fluidity of the platelet plasma membrane bilayer and by the exposure of a new pool of membranes to the outer surface of platelets, as monitored with trimethyl-ammonium-diphenylhexatriene (TMA-DPH) in platelets loaded with the non-fluorescent calcium probe analog MAPT. In contrast, low concentrations of quin2 did not potentiate shape change of platelets activated with ADP. Thus, shape change and aggregation can be influenced separately by intracellular Ca2+ chelators. We conclude that platelet responses are altered by the incorporation of intracellular calcium chelators at concentrations used to monitor intracellular calcium changes.
Lanza
F
F
INSERM U.311, Centre Régional de Transfusion Sanguine, Strasbourg, France.
Beretz
A
A
Kubina
M
M
Cazenave
J P
JP
D000634:Aminoquinolines / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000097:blood; D004161:Diphenylhexatriene / Q000031:analogs & derivatives; D016257:Fura-2; D006801:Humans; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism
D000634:Aminoquinolines; D001572:Benzofurans; D004161:Diphenylhexatriene; D012701:Serotonin; C033628:1-(4-(trimethylamino)phenyl)-6-phenylhexa-1,3,5-triene; C035739:Quin2; D002118:Calcium; D016257:Fura-2